Investigating the clinical effect of resveratrol in non-alcoholic fatty liver disease: A randomised, double blind, placebo-controlled trial

被引：0
|
作者：
Chachay, V. S. [1 ]
Martin, J. H. [2 ]
Prins, J. B. [1 ,3 ]
Whitehead, J. P. [3 ]
O'Moore-Sullivan, T. M. [3 ]
Lee, P. [2 ]
Franklin, M.
Klein, K. [4 ]
Taylor, P. J.
Ferguson, M. [5 ]
Coombes, J. S. [5 ]
Thomas, G. P. [1 ]
Cowin, G. J. [6 ]
Kirkpatrick, C. M. J. [7 ]
Macdonald, G. A. [2 ,8 ]
Hickman, I. J. [1 ,3 ]
机构：
[1] Univ Queensland, Diamantina Inst, Brisbane, Qld, Australia
[2] Sch Med Metrosouth, Brisbane, Qld, Australia
[3] Mater Med Res Inst, Brisbane, Qld, Australia
[4] Queensland Clin Trials & Biostat Ctr, Brisbane, Qld, Australia
[5] Sch Human Movement Studies, Brisbane, Qld, Australia
[6] Ctr Adv Imaging, Brisbane, Qld, Australia
[7] Monash Univ, Ctr Med Use & Safety, Melbourne, Vic 3004, Australia
[8] Univ Queensland, Dept Princess Alexandra Hospital, Brisbane, Qld, Australia
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2013年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：78 / 79
页数：2
相关论文
共 50 条
  • [21] Effect of Phytosomal Curcumin on Circulating Levels of Adiponectin and Leptin in Patients with Non-Alcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
    Mirhafez, Seyed Reza
    Farimani, Azam Rezaei
    Dehhabe, Maryam
    Bidkhori, Mohammad
    Hariri, Mitra
    Ghouchani, Bibi Fatemeh Nobakht Motlagh
    Abdollahi, Fatemeh
    JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2019, 28 (02) : 183 - 189
  • [22] Vitamin D supplementation for the treatment of non-alcoholic fatty liver disease: A randomized double blind placebo controlled trial
    Dabbaghmanesh, Mohammad Hossein
    Danafar, Farideh
    Eshraghian, Ahad
    Omrani, Gholamhossein Ranjbar
    DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2018, 12 (04) : 513 - 517
  • [23] Inhibition of 11β-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial
    Stefan, Norbert
    Ramsauer, Markus
    Jordan, Paul
    Nowotny, Bettina
    Kantartzis, Konstantinos
    Machann, Juergen
    Hwang, Jong-Hee
    Nowotny, Peter
    Kahl, Sabine
    Harreiter, Juergen
    Hornemann, Silke
    Sanyal, Arun J.
    Stewart, Paul M.
    Pfeiffer, Andreas F.
    Kautzky-Willer, Alexandra
    Roden, Michael
    Haering, Hans-Ulrich
    Fuerst-Recktenwald, Sabine
    LANCET DIABETES & ENDOCRINOLOGY, 2014, 2 (05): : 406 - 416
  • [24] Nigella sativa and inflammatory biomarkers in patients with non-alcoholic fatty liver disease: Results from a randomized, double-blind, placebo-controlled, clinical trial
    Darand, Mina
    Darabi, Zahra
    Yari, Zahra
    Saadati, Saeedeh
    Hedayati, Mehdi
    Khoncheh, Ahmad
    Hosseini-Ahangar, Behnam
    Alavian, Seyed Moayyed
    Hekmatdoost, Azita
    COMPLEMENTARY THERAPIES IN MEDICINE, 2019, 44 : 204 - 209
  • [25] Vitamin D for treatment of non-alcoholic fatty liver disease detected by transient elastography: A randomized, double-blind, placebo-controlled trial
    Lukenda Zanko, Vesna
    Domislovic, Viktor
    Trkulja, Vladimir
    Krznaric-Zrnic, Irena
    Turk-Wensveen, Tamara
    Krznaric, Zeljko
    Filipec Kanizaj, Tajana
    Radic-Kristo, Delfa
    Bilic-Zulle, Lidija
    Orlic, Lidija
    Dinjar-Kujundzic, Petra
    Poropat, Goran
    Stimac, Davor
    Hauser, Goran
    Mikolasevic, Ivana
    DIABETES OBESITY & METABOLISM, 2020, 22 (11): : 2097 - 2106
  • [26] Efficacy of Resveratrol Supplementation against Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Placebo-Controlled Clinical Trials
    Zhang, Chongyang
    Yuan, Weigang
    Fang, Jianguo
    Wang, Wenqing
    He, Pei
    Lei, Jiahui
    Wang, Chunxu
    PLOS ONE, 2016, 11 (08):
  • [27] The effect of nigella sativa supplementation on cardiometabolic outcomes in patients with non-alcoholic fatty liver: A randomized double-blind, placebo-controlled trial
    Rashidmayvan, Mohammad
    Vandyousefi, Sarvenaz
    Barati, Meisam
    Salamat, Shekoufeh
    Ghodrat, Sara
    Khorasanchi, Maryam
    Jahan-Mihan, Alireza
    Nattagh-Eshtivani, Elyas
    Mohammadshahi, Majid
    COMPLEMENTARY THERAPIES IN CLINICAL PRACTICE, 2022, 48
  • [28] Effect of resveratrol on non-alcoholic fatty liver disease
    Theodotou, Marios
    Fokianos, Konstantinos
    Moniatis, Demetris
    Kadlenic, Rudolf
    Chrysikou, Asimina
    Aristotelous, Andrea
    Mouzouridou, Alexia
    Diakides, John
    Stavrou, Eliza
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2019, 18 (01) : 559 - 565
  • [29] Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
    Chehrehgosha, Haleh
    Sohrabi, Masoud Reza
    Ismail-Beigi, Faramarz
    Malek, Mojtaba
    Babaei, Mohammad Reza
    Zamani, Farhad
    Ajdarkosh, Hossein
    Khoonsari, Mahmood
    Fallah, Afshin Eshghi
    Khamseh, Mohammad E.
    DIABETES THERAPY, 2021, 12 (03) : 843 - 861
  • [30] Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
    Haleh Chehrehgosha
    Masoud Reza Sohrabi
    Faramarz Ismail-Beigi
    Mojtaba Malek
    Mohammad Reza Babaei
    Farhad Zamani
    Hossein Ajdarkosh
    Mahmood Khoonsari
    Afshin Eshghi Fallah
    Mohammad E. Khamseh
    Diabetes Therapy, 2021, 12 : 843 - 861
12345